Accelerated -Rule-Out of acute Myocardial Infarction using prehospital copeptin and in-hospital troponin: The AROMI study

Eur Heart J. 2023 Oct 12;44(38):3875-3888. doi: 10.1093/eurheartj/ehad447.

Abstract

Aims: The present acute myocardial infarction (AMI) rule-out strategies are challenged by the late temporal release of cardiac troponin. Copeptin is a non-specific biomarker of endogenous stress and rises early in AMI, covering the early period where troponin is still normal. An accelerated dual-marker rule-out strategy combining prehospital copeptin and in-hospital high-sensitivity troponin T could reduce length of hospital stay and thus the burden on the health care systems worldwide. The AROMI trial aimed to evaluate if the accelerated dual-marker rule-out strategy could safely reduce length of stay in patients discharged after early rule-out of AMI.

Methods and results: Patients with suspected AMI transported to hospital by ambulance were randomized 1:1 to either accelerated rule-out using copeptin measured in a prehospital blood sample and high-sensitivity troponin T measured at arrival to hospital or to standard rule-out using a 0 h/3 h rule-out strategy. The AROMI study included 4351 patients with suspected AMI. The accelerated dual-marker rule-out strategy reduced mean length of stay by 0.9 h (95% confidence interval 0.7-1.1 h) in patients discharged after rule-out of AMI and was non-inferior regarding 30-day major adverse cardiac events when compared to standard rule-out (absolute risk difference -0.4%, 95% confidence interval -2.5 to 1.7; P-value for non-inferiority = 0.013).

Conclusion: Accelerated dual marker rule-out of AMI, using a combination of prehospital copeptin and first in-hospital high-sensitivity troponin T, reduces length of hospital stay without increasing the rate of 30-day major adverse cardiac events as compared to using a 0 h/3 h rule-out strategy.

Trial registration: ClinicalTrials.gov NCT02666326.

Keywords: Acute myocardial infarction; Chest pain; Copeptin; Diagnosis; Diagnostic tests; Early diagnosis; High-sensitivity cardiac troponin; Myocardial infarction; NSTEMI; Non–ST-elevation myocardial infarction; Rule out; Rule-out; Troponin.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Chest Pain
  • Emergency Medical Services*
  • Glycopeptides
  • Hospitals
  • Humans
  • Myocardial Infarction* / diagnosis
  • Predictive Value of Tests
  • Troponin
  • Troponin T

Substances

  • Troponin
  • copeptins
  • Troponin T
  • Glycopeptides
  • Biomarkers

Associated data

  • ClinicalTrials.gov/NCT02666326